Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience
暂无分享,去创建一个
R. Foà | R. Latagliata | G. Meloni | A. Frustaci | M. Breccia | G. Alimena | C. Girmenia | A. Micozzi | C. Cartoni | A. Matturro | G. Gentile | S. Trisolini | G. Loglisci | C. Minotti | S. Capria
[1] V. Pawar,et al. Cost-Effectiveness Of Posaconazole Versus Fluconazole Or Itraconazole In The Prevention Of Invasive Fungal Infections Among Neutropenic Patients In The United States , 2013 .
[2] K. Lyseng-Williamson. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. , 2011, PharmacoEconomics.
[3] E. Holler,et al. Clinical experience with posaconazole prophylaxis – a retrospective analysis in a haematological unit , 2011, Mycoses.
[4] M. Hallek,et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. , 2010, The Journal of antimicrobial chemotherapy.
[5] D. Liew,et al. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. , 2010, The Journal of antimicrobial chemotherapy.
[6] M. Vignetti,et al. Randomized trial of two schedules of low‐dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML‐19) , 2010, British journal of haematology.
[7] M. Sanz,et al. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT , 2010, Bone Marrow Transplantation.
[8] J. Jansen,et al. Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands , 2010, Annals of Hematology.
[9] Giuseppe Leone,et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study , 2010, Haematologica.
[10] P. Chandrasekar,et al. Safety of triazole antifungal drugs in patients with cancer. , 2010, The Journal of antimicrobial chemotherapy.
[11] M. Vignetti,et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Bob Löwenberg,et al. FLT3 inhibition as a targeted therapy for acute myeloid leukemia , 2009, Current opinion in oncology.
[13] D. Lebeaux,et al. Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults , 2009, Antimicrobial Agents and Chemotherapy.
[14] C. Girmenia. New generation azole antifungals in clinical investigation , 2009, Expert opinion on investigational drugs.
[15] M. Weinstein,et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] M. Rinaldi,et al. Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience , 2009, Antimicrobial Agents and Chemotherapy.
[17] H. Einsele,et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology , 2009, Haematologica.
[18] E. Steyerberg,et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] D. Denning,et al. Therapeutic drug monitoring for triazoles , 2008, Current opinion in infectious diseases.
[20] D. Kaul,et al. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[21] R. Foà,et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] F. Meunier,et al. The First European Conference on Infections in Leukaemia - ECIL1: a current perspective. , 2008, European journal of cancer.
[23] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] Raoul Herbrecht,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] L. Leibovici,et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] F. Abbona,et al. [A method to determine hospital costs associated with nosocomial infections]. , 2007, Annali di igiene : medicina preventiva e di comunita.
[27] L. Pagano,et al. Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality--SEIFEM-C Report. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] B. D. de Pauw,et al. Prophylaxis and aspergillosis--has the principle been proven? , 2007, The New England journal of medicine.
[29] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[30] O. Cornely,et al. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases , 2006, Mycoses.
[31] F. Mandelli,et al. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial , 2006, Leukemia.
[32] M. Vignetti,et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. , 2005, Blood.
[33] W. Leisenring,et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] M. Sanz,et al. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT , 2010, Bone Marrow Transplantation.
[35] B. Thiers. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .
[36] L. Pagano,et al. Design and Methods , 2022 .
[37] E. Estey,et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. , 1996, Leukemia.